| Product Features | |
|---|---|
| Immunogen: | Recombinant Cynomolgus CD153 / CD30L / TNFSF8 protein |
| Clonality: | Rabbit PAb |
| Cloneno: | |
| Isotype: | Rabbit IgG |
| Buffer: | 0.2 μm filtered solution in PBS |
| Reactivity: | Cynomolgus |
| Specificity: | Cynomolgus CD153 / CD30L / TNFSF8 |
| Application: | ELISA |
| Recommend dilution: | ELISA: 0.1-0.2 μg/mL. This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Cynomolgus CD153 / CD30L / TNFSF8 . The detection limit for Cynomolgus CD153 / CD30L / TNFSF8 is < 0.039 ng/well. |
| Storage: | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. |
| Background: | CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases. |
Cynomolgus TNFSF8 Antibody
$322.00 – $847.00